Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY:JNJ)

164.78 +9.61 (+6.19%)
Official Closing Price Updated: 7:00 PM EDT, Jul 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Johnson & Johnson

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
3 Top Dividend Stocks Yielding More Than 3% That You Shouldn't Hesitate to Buy Right Now
Via The Motley Fool
JNJ’s Stock Price Is Back in Rally Mode—The Time to Buy Is Now
Johnson & Johnson is back in rally mode after years of post-pandemic normalization and the impact of repositioning, set up to sustain higher prices for years. 
Via MarketBeat
Johnson & Johnson Lifts 2025 Outlook
Via The Motley Fool
Topics Intellectual Property
Why Johnson & Johnson Rallied Today
Via The Motley Fool
Topics World Trade
Johnson & Johnson Tops Q2 Estimates
Via The Motley Fool
Topics Intellectual Property
Johnson & Johnson Reportedly Halves Its Forecast Of US Tariff Impact To $200M, Sparks Retail Chatter
Via Stocktwits
What's Next: Johnson & Johnson's Earnings Preview
Via Benzinga
Gold, Bitcoin Surge As Trump Eyes Powell Ouster: What's Moving Markets Wednesday?
Volatility surged across interest rate-sensitive assets Wednesday after reports circulated that President Donald Trump may be preparing to remove Federal Reserve Chair Jerome Powell from his post. The... 
Via Benzinga
Topics Economy Government
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Johnson & Johnson Raises FY25 Forecast, Joins Rigetti Computing, Unity Software, Brighthouse Financial And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
What's going on in today's session: S&P500 movers
Let's delve into the developments on the US markets in the middle of the day on Wednesday. Below, you'll find the top gainers and losers within the S&P500 index during today's session. 
Via Chartmill
Johnson & Johnson (JNJ) Q2 2025 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Dow Health Giant J&J Surges After Hiking Outlook On Strong Quarterly Report
The company also easily beat second-quarter adjusted earnings and sales forecasts. 
Via Investor's Business Daily
Topics Stocks
Johnson & Johnson Lifts Annual Forecast After Strong Cancer Drugs, Medtech Performance
Johnson & Johnson beat Q2 estimates and raised its 2025 outlook, driven by strong cancer and MedTech sales despite Stelara declines. 
Via Benzinga
Johnson & Johnson (NYSE:JNJ) Reports Bullish Q2, Full-Year Sales Guidance is Optimistic
Multinational healthcare company Johnson & Johnson (NYSE:JNJ) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 5.8% year on year to $23.74 billion. The company’s full-year revenue... 
Via StockStory
Johnson & Johnson Outperforms Q2 Expectations; Provides Positive Outlook
Johnson & Johnson surpassed expectations in Q2 2025 with a notable increase in earnings per share and revenue. 
Via Talk Markets
Dow Futures Edge Up Even As Investors Maintain Caution: ASML, UAL, JNJ, BAC, GS Among Stocks To Watch
Via Stocktwits
Topics Stocks
3 Magnificent S&P 500 Dividend Stocks Down 16% to 20% to Buy and Hold Forever
Via The Motley Fool
Topics Stocks
Earnings Scheduled For July 16, 2025
Via Benzinga
10 Dividend Stocks to Double Up On Right Now
Via The Motley Fool
Topics Artificial Intelligence
Want to Generate at Least $1,000 in Passive Income Per Year? Invest $26,000 in This Dividend King Stock.
Via The Motley Fool
Topics Retirement
Should You Buy Johnson & Johnson Stock Before July 16th?
Via The Motley Fool
Topics Government World Trade
These 3 Undervalued Stocks Could Surge as Value Rotation Nears
A rotation back into value stocks may be imminent in today's market, giving investors a chance to expose themselves into a catch up play. 
Via MarketBeat
Topics ETFs Economy
Andrew Hill Dumps 38,000 Johnson & Johnson Shares in Q2 2025 Exit
Via The Motley Fool
Topics Regulatory Compliance
Kenvue CEO Thibaut Mongon Steps Down, Director Kirk Perry To Take On Interim CEO Role
Perry has previously worked with Circana, Google, and was with Procter and Gamble for 23 years. 
Via Stocktwits
Topics Government Stocks
This Stock Has Increased 4,720%: Here's Why It's Still a Buy
Via The Motley Fool
5 of the Best Stocks to Buy in July
These stocks are ready to pop higher. 
Via The Motley Fool
Trump Threatens 200% Pharma Tariffs, But Analyst Says This Stock Is Immune And Expected To 'Benefit' From Levies
Donald Trump's proposed 200% tariffs can squeeze the profit margins of pharma companies, but LLY is poised to "benefit" except for the rest. 
Via Benzinga
Topics Government World Trade
The Best High Yield Medical Device Stock to Invest $1,000 in Right Now
Via The Motley Fool
What Is Considered a Good Dividend Stock? 3 Healthcare Stocks That Fit the Bill
A steady dose of quality companies will keep your portfolio growing big and strong. 
Via The Motley Fool
Topics Intellectual Property
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.